Imu asx

Financial Times Close. Search the FT Search. Show more World link World. Show more US link US.

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board.

Imu asx

Imugene Limited. Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. About the company. IMU Stock Overview Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Earnings are forecast to grow Shareholders have been diluted in the past year. New minor risk - Share price stability Nov New minor risk - Profitability Oct No longer forecast to breakeven Oct Less than half of directors are independent Oct See more updates Recent updates. Forecast to breakeven in Jun Price target decreased by 9.

Corporate governance.

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes an off-the-shelf allogeneic cell therapy CAR T drug Azer-Cel azercabtagene zapreleucel which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia pox virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Financial Times Close. Search the FT Search.

Key events shows relevant news articles on days with large price movements. Race Oncology Ltd. RAC Immutep Ltd. IMM 8. Pilbara Minerals Ltd. PLS 0. Sayona Mining Ltd. SYA 2. Brainchip Holdings Ltd.

Imu asx

Market data is provided and copyrighted by Thomson Reuters and Morningstar. Click for restrictions. All rights reserved. ASX shareholders. Our Board. Corporate governance.

Urologist jupiter fl

Short selling activity Low. The Vanguard Group, Inc. Is IMU's price volatile compared to industry and market? Clinical Trials. Market resources. Show more Opinion link Opinion. Dr Eckstein has more than 20 years venture capital experience in the biopharmaceutical industry and 10 years operational experience in drug discovery and development. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Why list on ASX. Apr

Financial Times Close. Search the FT Search.

He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. All content on FT. September 25, James Mickleboro. Management Team. Show more US link US. Day Change. Public consultations. Health Care Pharmaceuticals and Biotechnology. The healthcare stock is roaring higher again on Friday. Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. Your password should be characters Invalid password: this word has been flagged as unsuitable for use as a secure password. Imugene Limited. In PTI and Yumanity, she chaired the audit committee and participated in the governance and compensation committees.